

Ongoing prospective trials

Poster Session 16

Saturday, 25 March
14:15 - 15:45

Location: Room Vienna, North Hall (Level 1)

Chairs: J. Bellmunt, Barcelona (ES)
M. Retz, Munich (DE)
S. Shariat, Vienna (AT)

Aims and objectives of this session

To show what is currently going on in oncologic urology and other fields in urology regarding multicentre prospective randomized studies.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:38 - 14:48

Overview on systematic reviews/meta analysis

S. Shariat, Vienna (AT)

206

A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)

By: Smith M.¹, Saad F.², Hussain M.³, Sternberg C.⁴, Fizazi K.⁵, Crawford D.⁶, Yamada K.⁷, Kappeler C.⁸, Kuss I.⁸, Tombal B.⁹

Institutes:¹Massachusetts General Hospital Cancer Center and Harvard Medical School, Dept. of Urologic Oncology, Boston, United States of America, ²University of Montreal, University of Montreal Hospital Center/CRCHUM, Montreal, Canada, ³Northwestern University Feinberg School of Medicine, Dept. of Hematology/Oncology, Chicago, United States of America, ⁴San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, ⁵Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, ⁶University of Colorado, Dept. of Urologic Oncology, Aurora, United States of America, ⁷Bayer Pharmaceuticals, Dept. of Oncology, Whippany, United States of America, ⁸Bayer Pharma AG, Dept. of Oncology, Berlin, Germany, ⁹Cancer Centre, Catholic University of Louvain (UCL), Dept. of Urology, Brussels, Belgium

207

Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers

By: Carmona Echeverria L.M.¹, Johnston E.², Shanmugabavan Y.³, Rowan A.⁴, Goh G.⁵, Scott R.³, Hung M.³, Gelinger M.⁶, Arya M.³, Emberton M.³, Freeman A.⁷, Punwani S.², Barrat D.⁸, Yipeng H.⁸, Attard G.⁹, Whitaker H.¹, Linch M.⁵, De Bono J.⁹, Swanston C.⁴, Ahmed H.³

Institutes:¹University College London, Dept. of Surgery and Interventional Science - Centre For Molecular Intervention, London, United Kingdom, ²University College London, UCL Centre For Medical Imaging, London, United Kingdom, ³University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ⁴Cancer Research UK, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ⁵University College London, Cancer Institute, London, United Kingdom, ⁶Institute of Cancer Research, Centre For Evolution and Cancer, London, United Kingdom, ⁷University College London, Dept. of Research Pathology, London, United Kingdom, ⁸University College London, UCL Centre For Medical Image Computing, London, United Kingdom, ⁹Institute of Cancer Research, Dept. of Clinical Studies, London, United Kingdom

208

KEYNOTE-365: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

By: Yu E.Y.², Wu H.¹, Schloss C.¹

Institutes:¹Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, ²Seattle Cancer Care Alliance, Dept. of Medicine, Seattle, United States of America

- 209 **Multi-institutional validation and assessment of training modalities in robotic surgery (the MARS project)**
 By: [Raison N.](#)¹, Ahmed K.¹, Aydin A.², Van Der Poel H.³, Mottrie A.⁴, Dasgupta P.²
 Institutes:¹King's College London, Mrc Centre For Transplantation, London, United Kingdom, ²King's College London, MRC Centre For Transplantation, London, United Kingdom, ³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴OLV Clinic, Dept. of Urology, Aalst, Belgium
- 210 **The effects of the human fetal estrogen estetrol (E4) in healthy men to estimate its potential use for the treatment of prostate cancer**
 By: [Dutman E.](#), Zimmerman Y., Coelingh-Bennink H.
 Institutes:Pantarhei Oncology BV, Zeist, The Netherlands
- 211 **PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miIBC)**
 By: [Necchi A.](#)¹, Mariani L.², Anichini A.³, Giannatempo P.¹, Raggi D.¹, Togliardi E.⁴, Calareso G.⁵, Nicolai N.⁶, Crippa F.⁷, Biononi D.⁶, Torelli T.⁶, Catanzaro M.⁶, Stagni S.⁶, Piva L.⁶, Salvioni R.⁶
 Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy
- 212 **IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)**
 By: [Gschwend J.](#)¹, Bellmunt J.², Castellano D.³, Daneshmand S.⁴, Hussain M.⁵, Nishiyama H.⁶, Powles T.⁷, Degaonkar V.⁸, Nguyen Duc A.⁹, Culine S.¹⁰
 Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, United States of America, ³Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, ⁴University of Southern California, Dept. of Oncology, Los Angeles, United States of America, ⁵Northwestern University, Dept. of Oncology, Chicago, United States of America, ⁶University of Tsukuba, Dept. of Oncology, Ibaraki, Japan, ⁷Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, ⁸Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, ⁹Roche, Dept. of Oncology, Basel, Switzerland, ¹⁰Hôpital Saint-Louis, Dept. of Oncology, Paris, France
- 213 **Phase 3 randomized trial of intravenous mannitol versus placebo prior to renal ischemia during partial nephrectomy: Impact on renal functional outcomes**
 By: [Spaliviero M.](#), Power N., Murray K., Sjoberg D., Benfante N., Bernstein M., Wren J., Russo P., Coleman J.
 Institutes:Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America
- 214 **A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma**
 By: Hutson T.¹, Xing D.², Dutcus C.², [Baig M.](#)³, Fishman M.⁴
 Institutes:¹Texas Oncology, Dallas, United States of America, ²Eisai, Woodcliff Lake, United States of America, ³Eisai, OBG, Woodcliff Lake, United States of America, ⁴H. Lee Moffitt, Cancer and Research Center, Tampa, United States of America
- 215 **A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy**
 By: [Grimm M-O.](#), Grünwald V., Bedke J.

Institutes:Jena University Hospital, Dept. of Urology, Jena, Germany

216

APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

By: [Necchi A.](#)¹, [Mariani L.](#)², [Anichini A.](#)³, [Giannatempo P.](#)¹, [Raggi D.](#)¹, [Togliardi E.](#)⁴, [Calareso G.](#)⁵, [Nicolai N.](#)⁶, [Crippa F.](#)⁷, [Salvioni R.](#)⁶

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy

217

An effective and acceptable cleaning method for re-use of catheters for intermittent catheterisation (IC)

By: [Wilks S.](#)¹, [Morris N.](#)², [Delgado D.](#)², [Prieto J.](#)¹, [Moore K.](#)³, [Macaulay M.](#)⁴, [Fader M.](#)¹

Institutes:¹University of Southampton, Dept. of Health Sciences, Southampton, United Kingdom, ²Bristol Urological Institute, Dept. of Learning and Research, Bristol, United Kingdom, ³University of Alberta, Faculty of Nursing, Alberta, Canada, ⁴University College London, Continence & Skin Technology Group, London, United Kingdom

15:36 - 15:43

Summary

J. Bellmunt